Alex Adjei, MD, PhD, FACP

PrintE-mail
Senior Vice President of Clinical Research
Professor and Chair, Department of Medicine
The Katherine Anne Gioia Chair in Cancer Medicine
Roswell Park Cancer Institute
Academic Scholar in Medicine
School of Medicine and Biomedical Sciences
State University of New York at Buffalo

Profile

Areas of Expertise: 
Lung cancer

Research

Research Interests: 
Drug Development (Phase I clinical trials; Phase II clinical trials)
Assessing toxicity, pharmacology and initial activity of novel agents for solid tumors
Development of biomarkers of drug effects
Mechanism of action and resistance of novel agents that inhibit cell signaling
Pharmacogenetics

Background Information

Education and Training: 
MD - University of Ghana Medical School, Legon, Ghana
PhD - University of Alberta, Edmonton, Alberta, Canada
Residency: 
Howard University, Washington, DC
Board Certification: 
Diplomate, Internal Medicine, American Board of Internal Medicine
Medical Oncology, American Board of Internal Medicine
Fellowships: 
Johns Hopkins School of Medicine, Baltimore, MD

Publications

Publications: 
  • Adjei AA, Schild SE, Rowland Jr KM, Stella PJ, Ziegler KLA, Gandara DR, Adjei AA, Molina JR, Dy GK, Mandrekar SJ, Zinner RG. Phase II trial of pemetrexed plus bevacizumab for second-line therapy of patients with advanced non-small-cell lung cancer: NCCTG and SWOG study N0426. Journal of clinical oncology 2010; 28(4):614-619
  • Bhaskarla A, Tang PC, Mashtare T, Nwogu CE, Demmy TL, Adjei AA, Reid ME, Yendamuri S. Analysis of second primary lung cancers in the SEER database. Journal of surgical research 2010; 162(1):1-6
  • Mandrekar SJ, Schild SE, Marks RS, Kuross SA, Rowland KM, Reuter NF, Allen Ziegler KL, Hillman SL, Qi Y, Adjei AA. Endpoints in phase II trials for advanced non-small cell lung cancer. Journal of thoracic oncology 2010; 5(1):3-9
  • Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Wellik LE, Witzig TE, Rajkumar SV, Adjei AA, Kumar S. Sorafenib, a dual Raf kinase/vascular endothelial growth factor receptor inhibitor has significant anti-myeloma activity and synergizes with common anti-myeloma drugs. Oncogene 2010; 29(8):1190-1202
  • Adjei AA. Pemetrexed pathway-associated germline polymorphisms: a useful tool for treatment individualization? Reply. Journal of clinical oncology 2010; 28(27):E484
  • Adjei AA, Salavaggione OE, Mandrekar SJ, Dy GK, Ziegler KLA, Endo C, Molina JR, Schild SE, Adjei AA. Correlation between polymorphisms of the reduced folate carrier gene (SLC19A1) and survival after pemetrexed-based therapy in non-small cell lung cancer: a North Central Cancer Treatment Group-based exploratory study. Journal of thoracic oncology 2010; 5(9):1346-1353
  • Bryce AH, Perez EA, Soori G, Wender DB, Rowland Jr K, Kugler JW, Adjei AA, Hillman SL, Mattar B, Jett JR. Phase II trial of oral topotecan and intravenous carboplatin with G-CSF support in previously untreated patients with extensive stage small cell lung cancer: A North Central Cancer Treatment Group Study. American journal of clinical oncology 2010; 33(4):353-357
  • Adjei AA. Targeting PI3-kinase-Akt: Complexities and potential strategies. Annals of oncology 2010; 21(Suppl. 2):21
  • Dy GK , Schild SE , Mandrekar S , Nair S , Wender DB , Steen PD , Molina JR , Rowland Jr KM , Hillman SL , Adjei AA. A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: north Central Cancer Treatment Group Study N0326. Cancer 2010; 116(24):5686-5693
  • Adjei AA, Jatoi A , Soori GS , Stella PJ , Rowland KM , Dakhil SR , Fitch TR , Flynn PJ , Dornfeld KJ , Henning GT , Foster N , Schild SE , Adjei AA. A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422). Annals of oncology 2010; 21(10):2040-2044
  • Lai J-P , Fernandez-Zapico ME , Adjei AA , Sanderson SO , Li J , Shire AM , Garrity-Park MM , Isomoto H , Aderca I , Han T , Nakamura I , Hu C , Elsawa SF , Yu C , Moser CD , Oseini AM , Roberts LR. The oncogenic effect of sulfatase 2 in human hepatocellular carcinoma is mediated in part by glypican 3-dependent Wnt activation. Hepatology (Baltimore, Md.) 2010; 52(5):1680-1689
  • Lai JP , Sanderson S , Adjei AA , Murphy LM , Aderca I , Shire AM , Hu CL , Moser CD , Yu CR , Sandhu DS , Roberts LR. Sulfatase 2 protects hepatocellular carcinoma cells against apoptosis induced by the PI3K inhibitor LY294002 and ERK and JNK kinase inhibitors. Liver international 2010; 30(10):1522-1528
  • Adjei AA, Chai F, Savage R, Means JA, Skupien D, Fetterly GJ, Ma W, Dy GK, Sosman JA, Puzanov I. A phase I dose-escalation trial evaluating ARQ 197 administered in combination with sorafenib in adult patients (pts) with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):3024
  • Calvo E, Millham RD, Denis LJ, Gualberto A, Bahleda R, Soria J, Hidalgo M, Tolcher AW, Ma W, Adjei AA. Phase (P) I study of PF-00299804 (PF) combined with figitumumab (FI; CP-751,871) in patients (pts) with advanced solid tumors (ASTs). Journal of clinical oncology 2010; 28(15 Suppl.):3026
  • Dilts DM, Adjei AA, Mandrekar SJ, Buckner JC, Minasian LM, Rienzo M, Ledsky R, Massett H. Impact of trial development time on accruals at CCOPs: The case of the MARVEL trial. Journal of clinical oncology 2010; 28(15 Suppl.):e16505
  • Dy GK, Adjei AA, Molina JR, Schild SE, Stella PJ, Lyss AP, Ansari RH, Ross HJ, Nelson GD, Mandrekar SJ, North Central Cancer Treatment Group . A randomized phase II study of gemcitabine (G) and carboplatin (C) with or without cediranib (AZD2171 [CED]) as first-line therapy in advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2010; 28(15 Suppl.):7603
  • Foster NR, Adjei AA, Schild SE, Molina JR, Jett JR, Kugler JW, Krook JE, Shi Q, Qi Y, Mandrekar SJ. Tumor response and progression-free survival (PFS) as potential surrogate endpoints for overall survival (OS) in extensive-stage small cell lung cancer (ES-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Journal of clinical oncology 2010; 28(15 Suppl.):7637
  • Ma W, Adjei AA, Wilhelm F, Bellemarre S, Messersmith WA, Ghalib MH, Dy GK, Freas E, Mani S, Jimeno A. Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors. Journal of clinical oncology 2010; 28(15 Suppl.):e13515
  • Mandrekar SJ, Hillman SL, Allen-Ziegler K, Jatoi A, Jett JR, Schild SE, Adjei AA. Impact of the algorithm for declaring exact progression date on progression-free survival (PFS) estimates in advanced lung cancer clinical trials. Journal of clinical oncology 2010; 28(15 Suppl.):7629
  • Pennella EJ, Schwartzberg L, Stepanski EJ, Obasaju CK, Marciniak MD, Faries DE, Pohl G, Girvan AC, Peltz G, Adjei AA. Interim results of an observational study evaluating the impact of ethnic origin on the effect of second-line treatment with pemetrexed (P) for advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2010; 28(15 Suppl.):e18055
  • Qi Y, Dy GK, Nelson GD, Schild SE, Mandrekar SJ, Adjei AA. Incidence of bleeding and thrombosis among elderly patients (pts) undergoing systemic chemotherapy in advanced non-small cell lung cancer (NSCLC): An analysis of North Central Cancer Treatment Group (NCCTG) trials. Journal of clinical oncology 2010; 28(15 Suppl.):e18093
  • Schild SE, Foster NR, Kugler JW, Northfelt DW, Thomas SP, Sarkaria JN, Rowland KM, Dy GK, Molina JR, Adjei AA. N0321: A phase I study of bortezomib, paclitaxel, carboplatin (CBDCA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2010; 28(15 Suppl.):7085
  • Iyer RV, Fakih M, Ma W, Tucker C, Levea C, Starostik P, Litwin A, Tan W, Khushalani NI, Adjei AA. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G) : 2010 Gastrointestinal Cancers Symposium. Journal of clinical oncology 2010; 28(15 Suppl.):Abstract# 258
  • Adjei AA, Christian M, Ivy P. Novel designs and end points for phase II clinical trials. Clinical cancer research 2009; 15(6):1866-1872
  • Demmy TL, Tomaszewski G, Dy GK, Yendamuri S, Nwogu C, Pendyala L, Ramnath N, Adjei AA. Thoracoscopic organ suffusion for regional lung chemotherapy (preliminary results). Annals of thoracic surgery 2009; 88(2):385-390; discussion 390-391
  • Dy GK, Adjei AA. Emerging therapeutic targets in non-small cell lung cancer. Proceedings of the American Thoracic Society 2009; 6(2):218-223
  • Foster NR, Jett JR, Marks RS, Kozelsky TF, Deming RL, Rowland Jr KM, Nelson GD, Schild SE, Mandrekar SJ, Adjei AA. Prognostic factors differ by tumor stage for small cell lung cancer: a pooled analysis of North Central Cancer Treatment Group trials. Cancer 2009; 115(12):2721-2731
  • Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA : a cancer journal for clinicians 2009; 59(2):111-137
  • McShane LM, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clinical cancer research 2009; 15(6):1898-1905
  • Qi Y, Adjei AA, Soori GS, Garces YI, Rowland KM, Krook JE, Tan AD, Mandrekar SJ, Schild SE, Sloan JA. Pretreatment quality of life is an independent prognostic factor for overall survival in patients with advanced stage non-small cell lung cancer. Journal of thoracic oncology 2009; 4(9):1075-1082
  • Sangha R, Vokes EE, Schiller JH, Saijo N, Goss G, Gaspar LE, Choy H, Baas P, Adjei AA, Lara Jr PN, Gandara DR. Cooperative group research endeavors in small-cell lung cancer: current and future directions. Clinical lung cancer 2009; 10(5):322-330
  • Wakelee H, Choy H, Goss G, Adjei A, Saijo N, Baas P, Schiller JH, Vokes EE, Edelman MJ, Putnam JB, Kernstine KH, Loo BW, Gandara DR. Cooperative group research efforts in thoracic malignancies 2009: a review from the 10th Annual International Lung Cancer Congress. Clinical lung cancer 2009; 10(6):395-404
  • Yang P, Perez E, Adjei AA, Sloan JA, Cunningham JM, Wampfler JA, Sun Z, Ziegler KLA, Hillman SH, Mandrekar SJ, Jett JR. Evaluation of glutathione metabolic genes on outcomes in advanced non-small cell lung cancer patients after initial treatment with platinum-based chemotherapy: an NCCTG-97-24-51 based study. Journal of thoracic oncology 2009; 4(4):479-485
  • Adjei AA, Huang H, Dy GK, Salavaggione OE, Endo C, Yu C. Functional characteristics of human epidermal growth factor receptor (EGFR) polymorphisms. European journal of cancer (Oxford, England : 1990) 2010; 8(7):175
  • Britten CD, Adjei AA, Millham R, Houk B, Wainberg ZA, Guthrie T, Dy G, LoRusso PM. First-in-human study of PF-04691502, a small molecule oral dual inhibitor of PI3K and mTOR in patients with advanced cancer: Preliminary report on safety and pharmacokinetics. European journal of cancer (Oxford, England : 1990) 2010; 8(7):121-122
  • Chow LQ, Salvati M, Chow P, Gupta A, Kopik J, Kurland J, Dy G, Adjei A. Translational approach using 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography (FDG-PET) in xenograft models to identify the optimal dosing regimen in a phase I trial of intercalated BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. Journal of thoracic oncology 2010; 5(12 Suppl. 7):S534-S535
  • Chow LQ, Salvati M, Chow P, Gupta A, Kopik J, Kurland J, Dy G, Adjei A. Using FDG-PET in xenograft models to identify dosing regimen in a phase I trial of intercalated BMS-690514 in combination with paclitaxel/carboplatin (PC) in patients with advanced or metastatic solid tumors. Journal of thoracic oncology 2010; 5(12 Suppl. 5):S404
  • Foster NR, Adjei AA, Schild SE, Molina JR, Jett JR, Kugler JW, Krook JE, Shi Q, Qi Y, Mandrekar SJ. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials. Cancer 2011; 117(6):1262-1271
  • Puehler F, Scholz A, Kissel M, Adjei A, Miner JN, Hitchcock M, Schmieder R, Mumberg D, Ziegelbauer K. Allosteric MEK inhibitor BAY 86-9766 (RDEA119) shows anti-tumor efficacy in mono-and combination therapy in preclinical models of hepatocellular carcinoma and pancreatic cancer. European journal of cancer (Oxford, England : 1990) 2010; 8(7):53
  • Soria JC, Gomez-Roca CA, Ware JA, Adjei AA, Brachmann RK, Groen HJM. A Phase Ib study to evaluate the pan-PI3K inhibitor GDC-0941 with paclitaxel and carboplatin with and without bevacizumab in non-small cell lung cancer patients. European journal of cancer (Oxford, England : 1990) 2010; 8(7):134
  • Weekes C, Dubowy R, Rajagopalan P, Iverson C, Sheedy B, Leffingwell D, Yeh L, Adjei AA, Von Hoff DD, Clendeninn N. A multi-center Phase 1, dose-escalation trial to determine the safety and pharmacokinetics/pharmacodynamics of BAY 86-9766 (RDEA119), a MEK inhibitor, in advanced cancer patients. European journal of cancer (Oxford, England : 1990) 2010; 8(7):116
  • Adjei A. SMAC mimetics as new anticancer agents. Annals of oncology 2011; 22(Suppl. 3):20
  • Adjei AA, Schwartz B, Garmey E. Early Clinical Development of ARQ 197, a Selective, Non-ATP-Competitive Inhibitor Targeting MET Tyrosine Kinase for the Treatment of Advanced Cancers. Oncologist 2011; 16(6):788-799
  • Shao H, Tang H, Salavaggione OE, Yu C, Hylander B, Tan W, Repasky E, Adjei AA, Dy GK. Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer. Journal of thoracic oncology 2011; 6(6):998-1005
  • Adjei AA. K-ras as a target for lung cancer therapy. Journal of thoracic oncology 2008; 3(6 Suppl. 2):S160-S163
  • Adjei AA, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Maloney L, Leong S, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Eckhardt SG. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. Journal of clinical oncology 2008; 26(13):2139-2146
  • Dy GK, Adjei AA. Systemic cancer therapy: evolution over the last 60 years. Cancer 2008; 113(7 Suppl.):1857-1887
  • Friday BB, Adjei AA. Advances in targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase cascade with MEK inhibitors for cancer therapy. Clinical cancer research 2008; 14(2):342-346
  • Friday BB, Yu C, Dy GK, Smith PD, Wang L, Thibodeau SN, Adjei AA. BRAF V600E disrupts AZD6244-induced abrogation of negative feedback pathways between extracellular signal-regulated kinase and Raf proteins. Cancer research 2008; 68(15):6145-6153
  • Furimsky AM, Green CE, Sharp LE, Catz P, Adjei AA, Parman T, Kapetanovic IM, Weinshilboum RM, Iyer LV. Effect of resveratrol on 17beta-estradiol sulfation by human hepatic and jejunal S9 and recombinant sulfotransferase 1E1. Drug metabolism and disposition 2008; 36(1):129-136
  • Furth AF, Mandrekar SJ, Tan AD, Rau A, Felten SJ, Ames MM, Adjei AA, Erlichman C, Reid JM. A limited sample model to predict area under the drug concentration curve for 17-(allylamino)-17-demethoxygeldanamycin and its active metabolite 17-(amino)-17-demethoxygeldanomycin. Cancer chemotherapy and pharmacology 2008; 61(1):39-45
  • Gilbert JA, Adjei AA, Reinholz MM, Lingle WL, Jenkins RB, Blair HE, Suman VJ, Giordano KF, Ingle JN, Reynolds CA, Goetz MP, Ames MM. Molecular analysis of metaplastic breast carcinoma: high EGFR copy number via aneusomy. Molecular cancer therapeutics 2008; 7(4):944-951
  • Grothey A, Buckner JC, Sloan JA, Sargent DJ, Loprinzi CL, Jaeckle KA, Perez EA, Alberts SR, Adjei AA, North Central Cancer Treatment Group. North Central Cancer Treatment Group--achievements and perspectives. Seminars in oncology 2008; 35(5):530-544
  • Lai JP, Thorgeirsson SS, Lee JS, Adjei AA, Sanderson SO, Nagorney DM, Shire AM, Zou H, Garrity-Park MM, Isomoto H, Aderca I, Guerrero RB, Jackson KK, Moser CD, Han T, Yu C, Sandhu DS, Roberts LR. Sulfatase 2 up-regulates glypican 3, promotes fibroblast growth factor signaling, and decreases survival in hepatocellular carcinoma. Hepatology (Baltimore, Md.) 2008; 47(4):1211-1222
  • Langer CJ, Saijo N, Baas P, Adjei AA, Vokes EE, Shepherd F, Choy H, Schiller J, Wakelee H, Gandara DR. Cooperative group portfolio in locally advanced non-small-cell lung cancer: are we making progress? . Clinical lung cancer 2008; 9(2):85-91
  • Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic proceedings 2008; 83(5):584-594
  • Peng Y, Feng Q, Wilk D, Adjei AA, Salavaggione OE, Weinshilboum RM, Yee VC. Structural basis of substrate recognition in thiopurine s-methyltransferase. Biochemistry 2008; 47(23):6216-6225
  • Sher T, Dy GK, Adjei AA. Small cell lung cancer. Mayo Clinic proceedings 2008; 83(3):355-367
  • Wakelee H, Choy H, Gandara DR, Gaspar L, Goss G, Adjei A, Saijo N, Baas P, Schiller J, Vokes E, Kernstine K, Putnam JB. Cooperative group research efforts in lung cancer 2008: focus on advanced-stage non-small-cell lung cancer. Clinical lung cancer 2008; 9(6):346-351
  • Wakelee H, Choy H, Shepherd F, Adjei A, Saijo N, Baas P, Schiller J, Vokes E, Langer C, Gandara DR. Cooperative group research efforts in lung cancer: focus on early-stage non-small-cell lung cancer. Clinical lung cancer 2008; 9(1):9-15
  • Yu C, Friday BB, Yang L, Atadja P, Wigle D, Sarkaria J, Adjei AA. Mitochondrial Bax translocation partially mediates synergistic cytotoxicity between histone deacetylase inhibitors and proteasome inhibitors in glioma cells. Neuro-oncology 2008; 10(3):309-319
  • Adjei AA. Novel small-molecule inhibitors of the vascular endothelial growth factor receptor. Clinical lung cancer 2007; 8 Suppl. 2:S74-S78
  • Adjei AA, Lathia C, Xia C, Jett JR, Hanson LJ, Croghan G, Reid JR, Marks R, Mandrekar SJ, Molina JR, Simantov R. Phase I trial of sorafenib in combination with gefitinib in patients with refractory or recurrent non-small cell lung cancer. Clinical cancer research 2007; 13(9):2684-2691
  • Adjei AA, Rajkumar SV, Tefferi A. Cancer symposium for the practitioner: introduction to solid tumors. Mayo Clinic proceedings 2007; 82(1):107-109
  • Barton DL, Adjei AA, Rummans T, Palmieri F, Hines S, Shanafelt T, Raymond J, Atherton P, Loprinzi CL, Sloan J. Phase II Evaluation of Desipramine for the Treatment of Hot Flashes. Supportive cancer therapy 2007; 4(4):219-224
  • Haluska P, Adjei AA, Gualberto A, Sharma A, Roberts ML, Yap TA, Molife LR, Molina JR, Yin D, Batzel GN, Shaw HM, de Bono JS. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clinical cancer research 2007; 13(19):5834-5840
  • Leil TA, Endo C, Adjei AA, Dy GK, Salavaggione OE, Reid JR, Ames MM, Adjei AA. Identification and characterization of genetic variation in the folylpolyglutamate synthase gene. Cancer research 2007; 67(18):8772-8782
  • Ramnath N, Adjei A. Inhibitors of Raf kinase and MEK signaling. Update on cancer therapeutics 2007; 2(3):111-118
  • Schild SE, Wender DB, Tenglin RC, Kugler JW, Soori GS, Graham DL, Marks RS, Vigliotti AP, Kozelsky TF, Hillman S, Bonner JA, Adjei A. Results of a phase II study of high-dose thoracic radiation therapy with concurrent cisplatin and etoposide in limited-stage small-cell lung cancer (NCCTG 95-20-53). Journal of clinical oncology 2007; 25(21):3124-3129
  • Yu C, Friday BB, Lai JP, McCollum A, Atadja P, Roberts LR, Adjei AA. Abrogation of MAPK and Akt signaling by AEE788 synergistically potentiates histone deacetylase inhibitor-induced apoptosis through reactive oxygen species generation. Clinical cancer research 2007; 13(4):1140-1148
  • Adjei AA, Blumenschein GR Jr, Mandrekar S, Hillman S, Gatzemeier U, Heigener D. Long-term safety and tolerability of sorafenib in patients with advanced non-small-cell lung cancer: a case-based review. Clinical lung cancer 2011; 12(4):212-217
  • Lorusso PM, Jin JY, Cheeti S, Chang I, Colburn D, Low JA, Leichman L, Berlin J, Adjei A, Dy G, Jimeno A, Graham RA. Pharmacokinetic dose-scheduling study of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with locally advanced or metastatic solid tumors. Clinical cancer research 2011; 17(17):5774-5782
  • Reinholz MM, Mandrekar SJ, Foster N, Meyers JP, Kitzmann KA, Jett JR, Bernath AM, Wender D, Zinner R, Dy G, Molina JR, Lingle WL, Adjei AA. Circulating tumor cell Cytokeratin-19 gene expression as a prognostic factor in lung cancer: Analysis based on North Central Cancer Treatment Group (NCCTG) clinical trials (N0423/426). Journal of thoracic oncology 2011; 6(6):S1076-S1077
  • Adjei AA, Sosman JA, Martell RE, Dy GK, Goff LW, Ma WW, Horn L, Fetterly GJ, Michael SA, Means JA, Chai F, Lamar M, Strauss GM, Chiang W, Jarboe J, Schwartz BE, Puzanov I. Efficacy in selected tumor types in a phase I study of the c-MET inhibitor ARQ 197 in combination with sorafenib : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3034
  • Besse B, Soria J, Gomez-Roca C, Ware JA, Adjei AA, Dy GK, Shankar G, Brachmann RK, Groen HJ. A phase Ib study to evaluate the PI3-kinase inhibitor GDC-0941 with paclitaxel (P) and carboplatin (C), with and without bevacizumab (BEV), in patients with advanced non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3044
  • Blumenschein GR, Molina JR, Lathia CD, Ong TJ, Roth D, Rajagopalan P, Fossella FV, Kies MS, Marks RS, Adjei AA, Sundaresan PR. Phase I dose-escalation study of sorafenib in combination with bevacizumab (B), paclitaxel (P), and carboplatin (C) for the treatment of advanced nonsquamous non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7565
  • Fetterly GJ, Thudium KE, Kalabus J, Murphy M, Zagst PD, Prey J, Kittleman E, Adjei AA, O'Connor TL, Blanco JG. Understanding the role of carbonyl reductase polymorphisms on doxorubicin-induced cardiotoxicity with population pharmacokinetics (PK) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):2606
  • Gore L, Lewis K, Von Hoff DD, Weiss GJ, Ramanathan RK, Adjei AA, Dy GK, Ma WW, Clendeninn NJ, Leffingwell DP, Sheedy B, Iverson C, Miner JN, Shen Z, Yeh L, Dubowy RL, Jeffers M, Rajagopalan P, Weekes CD. Safety, pharmacokinetics, and pharmacodynamics results from a phase I trial of BAY 86-9766 (RDEA119), a MEK inhibitor, in patients with advanced cancer : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3007
  • Ma WW, Messersmith WA, Dy GK, Freas E, Whitworth A, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Final results of a phase I study of the combination of a novel cell cycle inhibitor ON 01910.Na with gemcitabine in patients with advanced pancreatic and other solid tumors : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):3101
  • Pennella EJ, Pohl G, Girvan AC, Winfree K, Martinez B, Obasaju CK, Walker MS, Stepanski EJ, Schwartzberg LS, Adjei AA. Prospective observational comparison of outcomes in African American and Caucasian patients receiving second-line treatment with pemetrexed for advanced non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):e18008
  • Sosman JA, Adjei AA, LoRusso P, Michael SA, Dy GK, Bowditch A, Chmielowski B, Lee S, Walker RM, Faucette S, Izmailova ES, Bozon V, Ribas A. First-in-human, multicenter, dose-escalation, phase I study of the investigational drug TAK-733, an oral MEK inhibitor, in patients (pts) with advanced nonhematologic malignancies and melanoma : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):TPS145
  • Adjei A. Tailored chemotherapy in lung cancer. European journal of cancer (Oxford, England : 1990) 2007; 5(4):27-28 (Abstract #95)
  • Adjei A, Infante J, Eckhardt SG, Novello S, Jones S, Dy G, Huff A, Graham A, Burris H, Ottesen L. Phase Ib trial (NCT00619424, VEG109607) of pazopanib (GW786034) and erlotinib administered concurrently. European journal of cancer (Oxford, England : 1990) 2009; 7(2):546
  • Adjei AA. Sorafenib and combinations. Annals of oncology 2007; 18(Suppl. 4):18
  • Adjei AA. Novel targets for cancer therapy: looking beyond EGFR and angiogenesis. Journal of thoracic oncology 2007; 2(8 Suppl.):S284-S285
  • Adjei AA. Clinical trial designs in the era of targeted therapies. Journal of thoracic oncology 2007; 2(8 Suppl.):S297
  • Adjei AA, Cohen RB, Kurzrock R, Gordon GS, Hangauer D, Dyster L, Fetterly G, Barrientes S, Hong DS, Naing A. Results of a phase I trial of KX2-391, a novel non-ATP competitive substrate-pocket directed SRC inhibitor, in patients with advanced malignancies. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #3511
  • Adjei AA, Dy GK, Mandrekar SJ, Endo C, Salavaggione OE, Molina JR, Schild SE, Adjei AA. Pemetrexed pharmacogenomics: haplotype analyses of transport and activation/inactivation gene polymorphisms and the therapeutic outcome in non-small cell lung cancer, an NCCTG N0026 based study. Journal of thoracic oncology 2007; 2(8 Suppl.):S445
  • Adjei AA, Leil TA, Endo C, Dy GK, Salavaggione OE, Reid JR, Mandrekar S, Molina JR, Ames MM, Adjei AA. Functional polymorphisms in the human Folylpolyglutamate Synthase (FPGS) gene may influence efficacy and/or toxicity of Pemetrexed. Proceedings of the American Association for Cancer Research Annual Meeting 2007; 48:178-179
  • Foster NR, Qi Y, Krook JE, Kugler JW, Kuross SA, Jett JR, Molina JR, Schild SE, Adjei AA, Mandrekar SJ. Comparison of progression-free survival (PFS) and tumor response as endpoints for predicting overall survival (OS) in untreated extensive-stage small cell lung cancer (ED-SCLC): Findings based on North Central Cancer Treatment Group (NCCTG) trials. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #8085
  • Girvan AC, Peltz G, Pennella E, Pohl G, Faries D, Marciniak MD, Obasaju CK, Stepanski EJ, Schwartzberg LS, Adjei AA. An observational study of the impact of ethnicity on patients treated for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed: Preliminary results in African Americans. Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #e20624
  • Infante J, Bendell J, Dy GK, Ma WW, Novello S, Huff AC, Graham A, Burris H, Ottesen LH, Adjei AA. Phase Ib study of pemetrexed administered in combination with pazopanib (GW786034). Journal of thoracic oncology 2009; 4(9 Suppl. 1):S413
  • Iyer R, Khushalani N, Tan W, Litwin A, LeVea C, Hutson A, Tucker C, Ma W, Fakih M, Adjei A. A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G). European journal of cancer (Oxford, England : 1990) 2009; 7(2):391
  • Miner J, Yu C, Iverson C, Hamatake R, Cheney W, Chapman M, Adjei A, Quart B. Selective MEK Inhibitor RDEA119 exhibits efficacy in orthotopic hepatoma models and cytostatic potential in multiple cell based models of cancer. European journal of cancer (Oxford, England : 1990) 2008; 6(12):181
  • Molina JR, Foster NR, Nelson GD, Ger AVG, Steen PD, Nikcevich DA, Schild SE, Wright J, Adjei AA. Phase II trial (N0621) of the c-Src inhibitor AZD-0530 after 4 cycles of chemotherapy for patients with extensive stage small cell lung cancer (ED-SCLC). Journal of thoracic oncology 2009; 4(9 Suppl. 1):S465
  • Molina JR, Mandrekar SJ, Rowland K, Reuter NF, Jett JR, Marks R, Schild SE, Adjei AA. A phase IINCCTG "window of opportunity front-line" study of the mTOR inhibitor, CCI-779 (temsirolimus) given as a single agent in patients with advanced NSCLC. Journal of thoracic oncology 2007; 2(8 Suppl.):S413
  • Molina JR, Mandrekar SJ, Ziegler KLA, Soori GS, Rowland KM, Schild SE, Ivy P, Adjei AA. A phase II study of the VEGFR inhibitor pazopanib (P) in patients with newly diagnosed or relapsed malignant pleural mesothelioma (MPM): an NCCTG study. Journal of thoracic oncology 2009; 4(9 Suppl. 1):S456
  • Muindi JR, Adjei AA, Panasiewicz MA, Wu ZR, Tian L, Sucheston LE, Johnson CS, Trump DL, Fakih MG. Profiling serum vitamin D-3 metabolites in colorectal cancer patients on cholecalciferol supplementation.: Correlation with single nucleotide polymorphisms (SNPs) in the major vitamin D-3 metabolizing genes. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:827
  • Peltz G, Girvan AC, Schwartzberg LS, Pennella E, Pohl G, Bendaly EA, Walker MS, Faries DE, Obasaju CK, Stepanski E, Marciniak MD, Adjei AA. Baseline characteristics of patients enrolled in a study investigating the effects of ethnicity on treatment for non-small cell lung cancer (NSCLC) in the second-line setting with pemetrexed. Journal of thoracic oncology 2009; 4(9 Suppl. 1):S542
  • Qi YW, Molina JR, Adjei AA, Nelson G, Nikcevich DA, Rowland KM, Geeraerts LH, Dakhil SR, Obasaju CK. A randomized phase II study comparing a 21-day schedule of Pemetrexed (P) and Gemcitabine (G) versus biweekly P and G in patients with advanced Non-Small Cell Lung Cancer (NSCLC). Journal of thoracic oncology 2009; 4(9 Suppl. 1):S699-S700
  • Schild S, Graham D, Hillman S, Vora S, Yolanda G, Molina J, Shahidi H, Kugler J, Adjei A. Survival of patients (pts) treated with high-dose radiotherapy (RT) and concurrent chemotherapy for unresectable non-small cell lung cancer (NSCLC). Journal of clinical oncology 2009; 27(15 Suppl.):Abstract #7544
  • Schild SE, Graham DL, Hillman SL, Vora SA, Garces YI, Molina JR, Shahidi H, Kugler JW, Adjei AA. Survival of patients treated with high-dose radiotherapy & concurrent chemotherapy for unresectable non-small cell lung cancer. Journal of thoracic oncology 2009; 4(9 Suppl. 1):S336
  • Yu C, Tang H, Friday B, Miner JN, Chapman MS, Repasky E, Adjei AA. Inhibition of MAPK signaling enhances Sorafenib-mediated cytoxicity in human cancer cells in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2009; 50:892
  • Adjei AA, Gaedigk A, Simon SD, Weinshilboum RM, Leeder JS. Interindividual variability in acetaminophen sulfation by human fetal liver: implications for pharmacogenetic investigations of drug-induced birth defects. Birth defects research. Part A, Clinical and molecular teratology 2008; 82(3):155-165
  • Davis ID, Wiseman GA, Lee FT, Gansen DN, Hopkins W, Papenfuss AT, Liu Z, Moynihan TJ, Croghan GA, Adjei AA, Hoffman EW, Ingle JN, Old LJ, Scott AM. A phase I multiple dose, dose escalation study of cG250 monoclonal antibody in patients with advanced renal cell carcinoma. Cancer immunity 2007; 7 :13
  • de Bono JS, Attard G, Adjei A, Pollak MN, Fong PC, Haluska P, Roberts L, Melvin C, Repollet M, Chianese D, Connely M, Terstappen LW, Gualberto A. Potential applications for circulating tumor cells expressing the insulin-like growth factor-I receptor. Clinical cancer research 2007; 13(12):3611-3616
  • Hebbring SJ, Adjei AA, Baer JL, Jenkins GD, Zhang J, Cunningham JM, Schaid DJ, Weinshilboum RM, Thibodeau SN. Human SULT1A1 gene: copy number differences and functional implications. Human molecular genetics 2007; 16(5):463-470
  • Hildebrandt M, Adjei A, Weinshilboum R, Johnson JA, Berlin DS, Klein TE, Altman RB. Very important pharmacogene summary: sulfotransferase 1A1. Pharmacogenetics and genomics 2009; 19(6):404-406
  • Johnson EA, Marks RS, Mandrekar SJ, Hillman SL, Hauge MD, Bauman MD, Wos EJ, Moore DF, Kugler JW, Windschitl HE, Graham DL, Bernath AM Jr, Fitch TR, Soori GS, Jett JR, Adjei AA, Perez EA. Phase III randomized, double-blind study of maintenance CAI or placebo in patients with advanced non-small cell lung cancer (NSCLC) after completion of initial therapy (NCCTG 97-24-51). Lung cancer (Amsterdam, Netherlands) 2008; 60(2):200-207
  • Karp JE, Flatten K, Feldman EJ, Greer JM, Loegering DA, Ricklis RM, Morris LE, Ritchie E, Smith BD, Ironside V, Talbott T, Roboz G, Le SB, Meng XW, Schneider PA, Dai NT, Adjei AA, Gore SD, Levis MJ, Wright JJ, Garrett-Mayer E, Kaufmann SH. Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide. Blood 2009; 113(20):4841-4852
  • Lancet JE, Gojo I, Gotlib J, Feldman EJ, Greer J, Liesveld JL, Bruzek LM, Morris L, Park Y, Adjei AA, Kaufmann SH, Garrett-Mayer E, Greenberg PL, Wright JJ, Karp JE. A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia. Blood 2007; 109(4):1387-1394
  • Ma C, Mandrekar SJ, Alberts SR, Croghan GA, Jatoi A, Reid JM, Hanson LJ, Bruzek L, Tan AD, Pitot HC, Erlichman C, Wright JJ, Adjei AA. A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignancies. Cancer chemotherapy and pharmacology 2007; 59(2):207-215
  • Meng XW, Lee SH, Dai H, Loegering D, Yu C, Flatten K, Schneider P, Dai NT, Kumar SK, Smith BD, Karp JE, Adjei AA, Kaufmann SH. Mcl-1 as a buffer for proapoptotic Bcl-2 family members during TRAIL-induced apoptosis: a mechanistic basis for sorafenib (Bay 43-9006)-induced TRAIL sensitization. Journal of biological chemistry 2007; 282(41):29831-29846
  • Molina JR, Kaufmann SH, Reid JM, Rubin SD, Galvez-Peralta M, Friedman R, Flatten KS, Koch KM, Gilmer TM, Mullin RJ, Jewell RC, Felten SJ, Mandrekar S, Adjei AA, Erlichman C. Evaluation of lapatinib and topotecan combination therapy: tissue culture, murine xenograft, and phase I clinical trial data. Clinical cancer research 2008; 14(23):7900-7908
  • Okuno SH, Delaune R, Sloan JA, Foster NR, Maurer MJ, Aubry MC, Rowland KM Jr, Soori GS, Nikcevich DA, Kardinal CG, Northfelt DW, Adjei AA, North Central Cancer Treatment Group. A phase 2 study of gemcitabine and epirubicin for the treatment of pleural mesothelioma: a North Central Cancer Treatment Study, N0021. Cancer 2008; 112(8):1772-1779
  • Schild SE, Mandrekar SJ, Jatoi A, McGinnis WL, Stella PJ, Deming RL, Jett JR, Garces YI, Allen KL, Adjei AA, for the North Central Cancer Treatment Group. The value of combined-modality therapy in elderly patients with stage III nonsmall cell lung cancer. Cancer 2007; 110(2):363-368
  • Mandrekar SJ, Qi Y, Allen-Ziegler K, Hillman SL, Redman MW, Schild SE, Gandara DR, Adjei AA. Systematic evaluation of the impact of disease progression (DP) date determination on progression-free survival (PFS) in advanced lung cancer: A joint North Central Cancer Treatment Group (NCCTG) and Southwest Oncology Group (SWOG) investigation : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7005
  • Molina JR, Dy GK, Foster NR, Allen Ziegler KL, Adjei A, Rowland KM, Aubry M, Flynn PJ, Mandrekar SJ, Schild SE, Adjei AA, North Central Cancer Treatment Group (NCCTG). A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology: NCCTG N0626 study : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7513
  • Schild SE, Foster NR, Meyers JP, Olivier KR, Ross HJ, Molina JR, Stella PJ, Past LR, Garces YI, Adjei AA, North Central Cancer Treatment Group. Prophylactic cranial irradiation (PCI) in small cell lung cancer (SCLC): Findings from a North Central Cancer Treatment Group (NCCTG) pooled analysis : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7074
  • Wakelee HA, Dahlberg SE, Keller SM, Gandara DR, Graziano SL, Leighl NB, Adjei AA, Schiller JH, Eastern Cooperative Oncology Group. Interim report of on-study demographics and toxicity from E1505, a phase III randomized trial of adjuvant (adj) chemotherapy (chemo) with or without bevacizumab (B) for completely resected early-stage non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2011; 29(15 Suppl.):7013
  • An M-W, Mandrekar SJ, Branda ME, Hillman SL, Adjei AA, Pitot HC, Goldberg RM, Sargent DJ. Comparison of continuous versus categorical tumor measurement-based metrics to predict overall survival in cancer treatment trials. Clinical cancer research 2011; 17(20):6592-6599
  • Kaufmann SH, Karp JE, Litzow MR, Mesa RA, Hogan W, Steensma DP, Flatten KS, Loegering DA, Schneider PA, Peterson KL, Maurer MJ, Smith BD, Greer J, Chen Y, Reid JM, Ivy SP, Ames MM, Adjei AA, Erlichman C, Karnitz LM. Phase I and pharmacological study of cytarabine and tanespimycin in relapsed and refractory acute leukemia. Haematologica 2011; 96(11):1619-1626
  • Shao H, Gao C, Tang H, Zhang H, Roberts LR, Hylander BL, Repasky EA, Ma WW, Qiu J, Adjei AA, Dy GK, Yu C. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated anti-tumor efficacy in primary HCC cancer in vitro and in vivo. Journal of hepatology 2012; 56(1):176-183
  • Sharma N, Adjei AA. In the clinic: ongoing clinical trials evaluating c-MET-inhibiting drugs. Therapeutic advances in medical oncology 2011; 3(1 Suppl.):S37-S50
  • Groen H, Adjei AA, Dy GK, Ware JA, Shankar G, Brachmann RK, Besse B, Bahleda RK, Gomez-Roca C, Soria J. A Phase Ib Study to Evaluate the P13-Kinase Inhibitor GDC-0941 With Paclitaxel (P) and Carboplatin (C), With and Without Bevacizumab (BEV), in Patients With Advanced Non-small Cell Lung Cancer (NSCLC). European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S595
  • Adjei A. Biomarkers in Early Phase Therapy Trials. European journal of cancer (Oxford, England : 1990) 2011; 47(Suppl. 1):S62
  • Ramakrishnan V, Timm M, Haug JL, Kimlinger TK, Halling T, Wellik LE, Witzig TE, Vincent Rajkumar S, Adjei AA, Kumar S. Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycin. American journal of hematology 2012; 87(3):277-283
  • Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A phase I/II study of erlotinib in combination with the anti-insulin-like growth factor-1 receptor monoclonal antibody IMC-A12 (cixutumumab) in patients with advanced non-small cell lung cancer. Journal of thoracic oncology 2012; 7(2):419-426
  • Hennon MW, Hylander B, Morrison C, Miller A, Groman A, Dexter E, Yendamuri S, Demmy TL, Adjei A, Reid M, Repasky E, Nwogu C. Predicting NSCLC outcomes based on tumor growth in SCID mice. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1610
  • Huang H, Salavaggione OE, Tennant B, Iyer RV, Adjei AA. Biochemical characterization of recombinant woodchuck vascular endothelium growth factor (wVEGF). Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5156
  • Rosen L, LoRusso P, Ma WW, Goldman J, Weise A, Colevas AD, Adjei A, Yazji S, Shen A, Johnston S, Gates MR, Jones C, Musib L, De Crespigny A, Chan I, Sikic B. A first-in-human phase 1 study to evaluate the MEK1/2 inhibitor GDC-0973 administered daily in patients with advanced solid tumors. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #4716
  • Shao H, Tang H, Gao C, Zhang H, Dy G, Yu C, Adjei A, Roberts L. Dual targeting of mTORC1/C2 complexes enhances histone deacetylase inhibitor-mediated antitumor efficacy in primary HCC cancer in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #5363
  • Zhang H, Tang H, Shao H, Gao C, Hylander BL, Repasky EA, Dy GK, Ma WW, Yu C, Adjei AA. Mcl-1 downregulation plays a crucial role in the synergistic anticancer activities between PI-3 kinase inhibitors and histone deacetylase inhibitors in primary NSCLC tumors in vitro and in vivo. Proceedings of the American Association for Cancer Research Annual Meeting 2011; 52:Abstract #1
  • Ma WW, Messersmith WA, Dy GK, Weekes CD, Whitworth A, Ren C, Maniar M, Wilhelm F, Eckhardt SG, Adjei AA, Jimeno A. Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. Clinical cancer research 2012; 18(7):2048-2055
  • Reungwetwattana T, Molina JR, Mandrekar SJ, Allen-Ziegler K, Rowland KM, Reuter NF, Luyun RF, Dy GK, Marks RS, Schild SE, Jett JR, Adjei AA. Brief report: a phase II "window-of-opportunity" frontline study of the MTOR inhibitor, temsirolimus given as a single agent in patients with advanced NSCLC, an NCCTG study. Journal of thoracic oncology 2012; 7(5):919-922
  • Ramnath N, Daignault-Newton S, Dy GK, Muindi J, Adjei A, Kalemkerian GP, Cease KB, Stella PJ, Brenner DE, Johnson CS, Trump DL. A phase I/II clinical trial of intravenous (I.V.) calcitriol with fixed doses of cisplatin and docetaxel in advanced non-small cell lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e18118
  • Chen H, Modiano MR, Neal JW, Brahmer JR, Rigas JR, Jotte RM, Leighl NB, Liu L, Lisano JM, Adjei AA, Wakelee HA. A phase II multicenter study of aflibercept (AFL) in combination with cisplatin (C) and pemetrexed (P) in patients with previously untreated advanced/metastatic nonsquamous non-small cell lung cancer (NSCLC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7541
  • Dy GK, Molina JR, Qi Y, Ansari RH, Thomas SP, Ross HJ, Meyers JP, Adjei A, Mandrekar SJ, Adjei AA, North Central Cancer Treatment Group . N0821: A phase II first-line study of a combination of pemetrexed (P), carboplatin (C), and bevacizumab (B) in elderly patients with good performance status (PS < 2). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7555
  • Fetterly GJ, Liu B, Senzer NN, Amaravadi RK, Schilder RJ, Martin LP, LoRusso P, Papadopoulos KP, Adjei AA, Zagst PD, McKinlay MA, Weng DE, Graham M. Clinical pharmacokinetics of the Smac-mimetic birinapant (TL32711) as a single agent and in combination with multiple chemotherapy regimens. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #3029
  • Mandrekar SJ, Foster NR, Qi Y, Dy GK, Jatoi A, Molina JR, Jett JR, Stella PJ, Schild SE, Adjei AA, Alliance (North Central Cancer Treatment Group) . Impact of disease progression (DP) date determination method on post progression survival (PPS) and DP metrics in advanced lung cancer. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7605
  • Martell RE, Puzanov I, Ma WW, Santoro A, Dy GK, Goff LW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Simonelli M, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with hepatocellular carcinoma (HCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4117
  • Means-Powell JA, Adjei AA, Puzanov I, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Chai F, Lamar M, Schwartz BE, Sosman JA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with NRAS wild-type or mutant melanoma from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #8519
  • Puzanov I, Sosman JA, Santoro A, Martell RE, Dy GK, Goff LW, Ma WW, Fetterly GJ, Michael SA, Means-Powell JA, Chai F, Lamar M, Strauss GM, Zucali PA, Chiang WM, Jarboe J, Schwartz BE, Adjei AA. Safety and efficacy of MET inhibitor tivantinib (ARQ 197) combined with sorafenib in patients (pts) with renal cell carcinoma (RCC) from a phase I study. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #4545
  • Schild SE, Foster NR, Molina JR, Dy GK, Rowland KM, Sarkaria JN, Thomas SP, Northfelt DW, Kugler JW, Adjei AA, North Central Cancer Treatment Group (NCCTG) . N0321: A phase II study of bortezomib, paclitaxel, carboplatin (CBCDA), and radiotherapy (RT) for locally advanced non-small cell lung cancer (NSCLC). Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #7073
  • Farooq A, Dy GK, Demmy TL, Bogner P, Nowadly C, Tan W, Chen H, Yendamuri SS, Nwogu CE, Bushunow PW, Adjei AA, Ramnath N. Phase II study of perioperative chemotherapy with cisplatin (C) and pemetrexed (P) in non-small cell lung cancer (NSCLC) : ASCO Meeting Abstracts Part 1. Journal of clinical oncology 2012; 30(15 Suppl.):Abstract #e17535
  • Liu P, Morrison C, Wang L, Xiong D, Vedell P, Cui P, Hua X, Ding F, Lu Y, James M, Ebben JD, Xu H, Adjei AA, Head K, Andrae JW, Tschannen MR, Jacob H, Pan J, Zhang Q, Van den bergh F, Xiao H, Lo KC, Patel J, Richmond T, Watt M, Albert T, Selzer R, Anderson M, Wang J, Wang Y, Starnes S, Yang P, You M. Identification of somatic mutations in non-small cell lung carcinomas using whole-exome sequencing. Carcinogenesis 2012; 33(7):1270-1276
  • Adjei AA. C-MET inhibitors. Journal of thoracic oncology 2012; 7(6):S22
  • Peters S, Adjei AA. MET: a promising anticancer therapeutic target. Nature reviews. Clinical oncology 2012; 9(6):314-326

Cancer Can't Win

More patients are being diagnosed with cancer every day.

Here at Roswell Park Cancer Institute, we must continue to do what we do best – to understand, prevent and cure cancer. Because if we don’t, cancer wins. And Cancer Can’t Win.

  • With more than 3,000 scientific, academic and medical minds – Cancer Can’t Win.
  • When we are leading an advanced genetic program and creating next generation cancer vaccines to prevent it – Cancer Can’t Win.
  • When we are starting 13 new companies to advance our discoveries and share them with the world – Cancer Can’t Win.

Learn more about why Cancer Can’t Win

close